Regulation of the novel adipokines/ hepatokines fetuin A and fetuin B in gestational diabetes mellitus

Kralisch, Susan; Hoffmann, Annett; Lössner, Ulrike; Kratzsch, Jürgen; Blüher, Matthias; Stümvoll, Michael; Faßhauer, Mathias; Ebert, Thomas

doi:10.1016/j.metabol.2016.11.017

Cited by 55 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a recently published study (Kralisch et al 2017), fetuin B levels during pregnancy were increased in women with GDM compared to non-diabetic pregnant women with a drop in concentrations after delivery. Here we found equally increased fetuin B levels during pregnancy in both healthy pregnant and GDM groups with a significant decrease after delivery.…”

Section: Vol 67mentioning

confidence: 99%

Changes in Plasma Concentrations and mRNA Expression of Hepatokines Fetuin A, Fetuin B and FGF21 in Physiological Pregnancy and Gestational Diabetes Mellitus

Šimják¹,

Cinkajzlová²,

Anderlová³

et al. 2018

Physiol Res

View full text Add to dashboard Cite

We measured plasma concentrations, adipose tissue and placental mRNA expression of hepatokines fetuin A, fetuin B and fibroblast growth factor 21 (FGF21) in 12 healthy pregnant women (P group), 12 pregnant women with gestational diabetes (GDM) and 10 healthy non-pregnant women (N group) to explore their potential role in the etiopathogenesis of GDM. GDM and P group had comparable BMI, C-reactive protein (CRP) and glycated hemoglobin levels while IL-10 and TNF-α levels were higher in GDM group. Fetuin A and fetuin B levels were higher in pregnancy as compared to N group and decreased after delivery with no apparent influence of GDM. In contrast, the pattern of changes of circulating FGF21 levels differed between GDM and P group. Fetuin A concentrations positively correlated with CRP, TNF-α mRNA expression in adipose tissue and IL-6 mRNA expression in placenta. Fetuin B positively correlated with CRP. FGF21 levels correlated positively with IFN-γ mRNA in adipose tissue and inversely with IL-8 mRNA in the placenta. Taken together, fetuin A and fetuin B levels were increased during pregnancy regardless of the presence of GDM. In contrast, FGF21 patterns differed between healthy pregnant women and GDM patients suggesting a possible role of this hepatokine in the etiopathogenesis of GDM.

show abstract

Section: Vol 67mentioning

confidence: 99%

Changes in Plasma Concentrations and mRNA Expression of Hepatokines Fetuin A, Fetuin B and FGF21 in Physiological Pregnancy and Gestational Diabetes Mellitus

Šimják¹,

Cinkajzlová²,

Anderlová³

et al. 2018

Physiol Res

View full text Add to dashboard Cite

show abstract

“…Serum fetuin A levels are elevated in adults and children with the metabolic syndrome [7] and are positively associated with obesity and visceral adiposity [1, 2, 8-10]. Elevated serum levels have also been described to be associated with type 2 diabetes (T2D) and gestational diabetes [10-19]. Its role in secondary complications and cardiovascular disease has been controversially discussed [20-23].…”

Section: Introductionmentioning

confidence: 99%

Relationship of Serum Fetuin A with Metabolic and Clinical Parameters in German Children and Adolescents with Type 1 Diabetes

et al. 2017

View full text Add to dashboard Cite

Background and Aim: The hepatokine fetuin A is upregulated in the metabolic syndrome and in type 2 diabetes (T2D), while its role in adolescent type 1 diabetes (T1D) is unclear. We assessed the relationship between circulating fetuin A levels and metabolic control, comorbidities, and complications in adolescent T1D patients. Methods: We studied the relationship between serum fetuin A and clinical diabetes-related data from the DPV registry (Diabetes-Patienten-Verlaufsdokumentation) in 172 adolescent T1D patients with early-onset (<5 years) long-standing (>10 years) T1D. Fetuin A levels were further compared between adolescent T1D and T2D patients. Results: Serum fetuin A levels in T1D patients (mean 0.267 ± 0.043 g/L) did not correlate with age, diabetes duration, gender, body mass index (BMI), glycated hemoglobin, serum lipid levels, blood pressure, celiac or thyroid disease, nephropathy, or retinopathy. An association of fetuin A levels with insulin requirements was only evident within the subgroup of overweight T1D patients (r_s = 0.439, p = 0.028, n = 25, BMI >90th percentile), disappearing after adjustment for multiple testing. Adolescent T1D patients showed distinctly lower fetuin A levels than patients with T2D (p ≤ 0.001). Conclusion: Overall, we did not observe a clinically relevant association of fetuin A levels with surrogate parameters for insulin sensitivity in our juvenile T1D cohort. A correlation with insulin requirements was detectable in overweight patients only. We hypothesize that multiple factors, such as obesity, puberty, inadequate metabolic control, and hepatic steatosis, have to add up before a clinically relevant effect of fetuin A on insulin sensitivity becomes evident.

show abstract

“…This protein was strongly associated with energy metabolism (9). Several case-control and cross-sectional studies have reported that circulating fetuin-B concentration was obviously elevated in patients with NAFLD, T2DM, GDM, and PCOS (13,14,15). However, most of these studies were preliminary explorations and did not adequately demonstrate the association of fetuin-B with IR in humans nor use state-of-the-art methodology.…”

Section: Discussionmentioning

confidence: 99%

“…In a clinical study, serum fetuin-B was found to be strongly associated with triglyceride (TG) contents in the liver, abdominal obesity, IR, and early insulin secretion stimulated by glucose (11,12). It has also been reported that the fetuin-B concentrations in patients with nonalcoholic fatty liver (NAFLD), T2DM, polycystic ovary syndrome (PCOS), and gestational diabetes mellitus (GDM) are signi cantly increased compared with healthy controls (13,14,15). Furthermore, fetuin-B is also considered to be related to cardiovascular disease (CVD) and chronic kidney disease (CKD) (16,17).…”

Section: Introductionmentioning

confidence: 99%

High serum Fetuin-B levels are associated with the presence of metabolic syndrome in women: a case-controlled study and interventional studies

Xue¹,

Ren²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies have investigated circulating fetuin-B and its association with type 2 diabetes mellitus (T2DM). However, the variation and regulatory factors of serum fetuin-B levels in individuals with metabolic syndrome (MetS) have not been explained. This study evaluated circulating fetuin-B concentrations in newly diagnosed individuals with MetS and analyzed the impacts of blood glucose, insulin, and glucagon-like peptide-1 receptor agonists (GLP-1RA) treatment on circulating fetuin-B in vivo.Methods: A total of 377 women (192 MetS and 185 healthy subjects) were recruited for cross-sectional study. The euglycemic-hyperinsulinemic clamp (EHC) and oral glucose tolerance test (OGTT) were implemented in healthy women and those with MetS. Serum fetuin-B were examined by an ELISA kit. For the GLP-1RA intervention experiment, twenty-four women with MetS were treated with Liraglutide for 6 months. Results: Serum fetuin-B levels were markedly higher in women with MetS as compared to healthy women. Circulating fetuin-B reflected a positive correlation with body mass index, waist hip ratio (WHR), the percentage of fat in vivo (FAT%), triglyceride, fasting blood glucose, 2-hour blood glucose after glucose overload, glycosylated hemoglobin, fasting plasma insulin, 2-hour plasma insulin after glucose overload, homeostasis model assessment of insulin resistance (HOMA-IR), visceral adiposity index (VAI), and lipid accumulation product (LAP). Multivariate linear regression analyses demonstrated that triglyceride and WHR were independently related factors of serum fetuin-B. Serum fetuin-B levels were related to MetS by binary logistic regression analysis. In fact, serum fetuin-B was markedly elevated in healthy women after glucose loading and in MetS women during the EHC. After six months of GLP-1RA intervention, serum fetuin-B levels in MetS subjects decreased following improvement of metabolism and insulin sensitivity. Conclusions: Serum fetuin-B levels were associated with MetS and its components and regulated by glucose and insulin. GLP-1RA treatment can reduce serum fetuin-B levels in women with MetS. Clinical Trial Registration Number: ChiCTR-OCS-13003185. Registered 02/01 2016, http://www.chictr.org.cn/showproj.aspx?proj=6374

show abstract

Regulation of the novel adipokines/ hepatokines fetuin A and fetuin B in gestational diabetes mellitus

Cited by 55 publications

References 32 publications

Changes in Plasma Concentrations and mRNA Expression of Hepatokines Fetuin A, Fetuin B and FGF21 in Physiological Pregnancy and Gestational Diabetes Mellitus

Changes in Plasma Concentrations and mRNA Expression of Hepatokines Fetuin A, Fetuin B and FGF21 in Physiological Pregnancy and Gestational Diabetes Mellitus

Relationship of Serum Fetuin A with Metabolic and Clinical Parameters in German Children and Adolescents with Type 1 Diabetes

High serum Fetuin-B levels are associated with the presence of metabolic syndrome in women: a case-controlled study and interventional studies

Contact Info

Product

Resources

About